Concepedia
Statistics
Publications
28
Citations
3.4K
H-Index
22
Active since
1998
Affiliations
AstraZeneca (United Kingdom)(Current)
Eli Lilly (United States)
AstraZeneca (Sweden)
Harvard University
University of Dundee
Matthew P. Coghlan is an author at AstraZeneca (United Kingdom) specializing in medicine, metabolic syndrome, and physiology.
Top concepts
MedicinePhysiologyMetabolic SyndromeHealthDiabetesBiochemistryMetabolismCell BiologyPharmacologyEndocrinology
Publications per year
1998–2024
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription
Matthew P. Coghlan, Ainsley A. Culbert, Darren A.E. Cross et al. · Chemistry & Biology · 2000 · 888 citations · Full text
Biochemistry, Natural Sciences, Glycobiology +7
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe et al. · JCI Insight · 2020 · 439 citations · Full text
Pharmacotherapy, Experimental Pharmacology, Insulin Signaling +20
Robust anti‐obesity and metabolic effects of a dual <scp>GLP</scp> ‐1/glucagon receptor peptide agonist in rodents and non‐human primates
Susan Henderson, Anish Konkar, David C. Hornigold et al. · Diabetes Obesity and Metabolism · 2016 · 233 citations · Full text
Inhibition of GSK-3 Selectively Reduces Glucose-6-Phosphatase and Phosphoenolpyruvate Carboxykinase Gene Expression
Pamela A. Lochhead, Matthew P. Coghlan, Simon Q.J. Rice et al. · Diabetes · 2001 · 215 citations · Full text
Metabolic Remodeling, Insulin Signaling, Metabolic Syndrome +19
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms, Michael E. Christe, Kyla Collins et al. · Journal of Clinical Investigation · 2021 · 204 citations · Full text
1–5 of 28